(ARGX) argenx - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US04016X1019

FcgRn-Blocker, MusK-Agonist, Il6-Antibody, FcRn-Inhibitor, Galectin10-Antibody

Stock: Biotechnology
Age 8.7y

MCap 49,507m
Avg Vol 384K (308M USD)

Beta 0.423
Volatility 35.46%

EPS (Earnings per Share)

EPS CAGR: 146.36%
EPS Trend: 86.5%

Last SUE: -3.84
Qual. Beats: 0

Revenue

Rev. CAGR: 173.11%
Rev. Trend: 45.1%

Last SUE: 1.33
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	35.5%
Value at Risk 5%th	49.6%
Relative Tail Risk	-15.03%

Reward TTM
Sharpe Ratio	0.83
Alpha	18.79
CAGR/Max DD	0.78

Character TTM
Hurst Exponent	0.410
Beta	0.423
Beta Downside	0.456

Drawdowns 3y
Max DD	38.20%
Mean DD	10.90%
Median DD	7.76%

Description: ARGX argenx December 04, 2025

argenx SE (NASDAQ: ARGX) is a commercial-stage biotech headquartered in Amsterdam that focuses on FcRn-targeted antibodies for autoimmune disorders. Its marketed products, VYGART (efgartigimod) and VYGART HYTRULO, are approved in the U.S. and EU for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company’s pipeline expands beyond FcRn inhibition to include MuSK agonists (ARGX-119), IL-6 blockade (ARGX-109), and novel targets such as Galectin-10 (ARGX-118), with multiple collaborations spanning AbbVie, Zai Lab and Chugai to accelerate development across North America, Europe and Asia.

Key recent metrics: as of Q2 2024, argenx reported $210 million in total revenue, a 45 % YoY increase driven by VYGART sales, and held $1.3 billion in cash and marketable securities, giving it ~18 months of runway at current burn. The biotech sector’s average forward-price-to-sales multiple remains around 12×, while argenx trades at roughly 9× forward sales, suggesting a relative discount that may reflect execution risk in later-stage trials. A macro driver is the growing demand for targeted immunotherapies, with global autoimmune disease therapeutics projected to exceed $150 billion by 2028, supporting long-term market expansion for FcRn-based agents.

For a deeper quantitative assessment of argenx’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: 1.62b TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 12.03 > 1.0
NWC/Revenue: 113.7% < 20% (prev 142.9%; Δ -29.24% < -1%)
CFO/TA 0.07 > 3% & CFO 479.8m > Net Income 1.62b
Net Debt (-2.04b) to EBITDA (844.1m): -2.42 < 3
Current Ratio: 5.60 > 1.5 & < 3
Outstanding Shares: last quarter (65.7m) vs 12m ago 10.53% < -2%
Gross Margin: 77.07% > 18% (prev 0.91%; Δ 7616 % > 0.5%)
Asset Turnover: 70.36% > 50% (prev 54.91%; Δ 15.45% > 0%)
Interest Coverage Ratio: 156.2 > 6 (EBITDA TTM 844.1m / Interest Expense TTM 3.96m)

Altman Z'' (< 1.1 .. > 2.6) 3.50

A: 0.67 (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b
B: -0.16 (Retained Earnings -1.16b / Total Assets 7.18b)
C: 0.10 (EBIT TTM 618.3m / Avg Total Assets 5.99b)
D: -0.99 (Book Value of Equity -1.07b / Total Liabilities 1.08b)
Altman-Z'' Score: 3.50 = A

ValueRay F-Score (Strict, 0-100) 72.09

1. Piotroski: 6.0pt
2. FCF Yield: 1.04%
3. FCF Margin: 11.24%
4. Debt/Equity: 0.01
5. Debt/Ebitda: -2.42
6. ROIC - WACC: 2.05%
7. RoE: 32.57%
8. Revenue Trend: 45.08%
9. EPS Trend: 86.45%

What is the price of ARGX shares?

As of January 23, 2026, the stock is trading at USD 827.02 with a total of 407,154 shares traded.
Over the past week, the price has changed by +1.69%, over one month by -2.94%, over three months by +1.58% and over the past year by +29.25%.

Is ARGX a buy, sell or hold?

argenx has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy ARGX.

Strong Buy: 14
Buy: 7
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARGX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	1007.3	21.8%
Analysts Target Price	1007.3	21.8%
ValueRay Target Price	1042.6	26.1%

ARGX Fundamental Data Overview January 20, 2026

P/E Trailing = 34.247
P/E Forward = 27.3973
P/S = 13.4411
P/B = 8.1216
P/EG = 0.8901
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 45.62b USD (49.51b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
EV/FCF = 96.35x (Enterprise Value 45.62b / FCF TTM 473.5m)
FCF Yield = 1.04% (FCF TTM 473.5m / Enterprise Value 45.62b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 6.36 (Enterprise Value 45.62b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.14% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 7.47% (E(49.51b)/V(49.55b) * Re(7.47%) + D(43.2m)/V(49.55b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 6.42%
[DCF Debug] Terminal Value 72.74% ; FCFF base≈473.5m ; Y1≈310.8m ; Y5≈141.8m
Fair Price DCF = 82.56 (EV 3.07b - Net Debt -2.04b = Equity 5.11b / Shares 61.9m; r=7.47% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 86.45 | EPS CAGR: 146.4% | SUE: -3.84 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 173.1% | SUE: 1.33 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.82 | Chg30d=-0.075 | Revisions Net=-7 | Analysts=9
EPS next Year (2026-12-31): EPS=25.45 | Chg30d=+0.160 | Revisions Net=-6 | Growth EPS=+70.9% | Growth Revenue=+38.7%

Additional Sources for ARGX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle